光学切片市场 - 全球产业规模、份额、趋势、机会及预测（按技术、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球光学切片市场预计将从 2025 年的 14.6 亿美元成长到 2031 年的 23.2 亿美元，复合年增长率为 8.02%。

光学活检是一种非侵入性诊断方法，它利用光与组织的相互作用来获取即时病理数据，无需进行物理组织取样。市场成长的主要驱动力是肿瘤疾病发生率的上升以及早期疾病检测的重要性，而早期疾病检测需要频繁且微创的诊断程序。根据美国癌症协会预测，到2024年，美国预计将新增2,001,140例癌症病例，日益加重的疾病负担推动了对能够提供即时结果以迅速制定治疗方案的快速诊断方法的需求。

儘管光学成像设备具有许多显而易见的临床优势，例如提高诊断速度和减轻患者负担，但其市场发展仍面临高昂的资金投入等重大障碍。购置和维护先进光学成像设备的成本高昂，限制了其普及，尤其是在医疗基础设施尚未完善且小规模的医疗机构。这种资金限制迫使医疗机构进行严格的成本效益分析，导致这些诊断系统的采购速度缓慢，并阻碍了其更广泛的市场渗透。

市场驱动因素

光学成像技术的进步正从根本上改变光学活检领域，提高了诊断准确率，并实现了即时组织评估。萤光导引手术和先进的光学同调断层扫描（OCT）等创新技术使外科医生能够在手术中可视化肿瘤边缘，从而最大限度地减少再次手术的需要。近期，一种结合了药物和医疗设备技术的先进成像平台获得监管部门核准，这便是该领域进步的一个显着例证，该平台具有卓越的检测能力。根据 Lumicell 公司 2024 年 4 月发布的新闻稿，新核准的LumiSystem 在乳癌乳房保留手术中检测残留癌的诊断准确率高达 84%，解决了传统组织病理学面临的一大难题，并推动了市场成长。

全球癌症和慢性疾病的日益普及是推动光学活检系统普及应用的主要因素。随着恶性肿瘤发病率的上升，迫切需要快速、非侵入性的诊断工具，以便在不耗费传统组织样本处理时间的情况下，处理日益增长的患者数量。根据国际癌症研究机构（IARC）2024年2月发布的数据，预计到2050年，新增癌症病例将超过3,500万例，比2022年的估计值增加77%。疾病负担的快速成长与对先进诊断辅助设备的需求成长直接相关，Maunakea Technologies公司2023年销售额成长42%至1050万欧元便印证了这一点。该公司销售成长的主要驱动力是市场对共聚焦雷射内视镜解决方案日益增长的需求。

市场挑战

高昂的资本投入是全球光学切片市场扩张的主要障碍。这些诊断系统的实施需要大量的初期投入，限制了预算有限的医疗机构使用。这种经济负担不仅包括初始购买成本，还包括日常维护、校准以及医护人员的专业训练费用。因此，小规模的社区医院和诊所往往会延后采用这项技术，而选择更传统、更经济的诊断方法。这实际上限制了光学活检系统的应用范围，使其仅限于资金雄厚的大型医疗中心。

这种经济限制直接阻碍了市场渗透，延长了潜在买家的决策流程。医疗机构管理者被迫进行严格的成本效益分析，这往往导致采购延迟或采购申请被拒绝。医疗保健产业面临的更广泛的财务压力进一步加剧了这种犹豫不决。例如，美国医学会 (AMA) 指出，2024 年联邦医疗保险医师收费标准将下调 3.4%，造成了更具挑战性的财政环境。报销水准的降低限制了用于购买先进设备的自由支配资金，最终减缓了光学活检市场的整体成长速度。

市场趋势

光学成像与机器人辅助手术系统的融合，透过将细胞级视觉化直接整合到机器人平台中，正在为精准手术建立一种新的范式。这种协同作用解决了术中切缘评估的关键难题，使外科医生能够在无需进行冰冻切片检查的情况下识别潜在病变并保留健康组织。这种整合使得在经口机器人手术（TORS）等复杂手术过程中能够进行即时决策，而识别肿瘤切缘在这些手术中尤其具有挑战性。根据Maunakea Technologies公司2025年1月发布的新闻稿，一项采用这种整合方法的病例係列研究表明，外科医生在所有病例中均实现了术后切缘阴性。

在将诊断工作流程整合到单一导管解决方案的临床需求驱动下，多模态混合成像平台的商业化进程正在迅速推进。这些平台将高解析度结构影像（例如光同调断层扫瞄(OCT)）与功能性生理测量资料融合，从而优化心臟病介入治疗策略。这种整合透过同时提供形态学和生理学数据，最大限度地减少了导管更换次数，并提高了经经皮冠状动脉介入治疗 (PCI) 期间的决策效率。正如 SpectraWAVE 公司在 2025 年 10 月发布的新闻稿中所强调的，该公司凭藉其人工智慧驱动的 X1-FFR 平台，在短短两年多的时间里获得了第五次 FDA核准。这印证了产业正加速向多功能一体化光学诊断工具转型。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球光学切片市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（光同调断层扫瞄（OCT）、雷射、红外线、萤光、光谱学、其他）
  • 依应用领域（肿瘤科与非肿瘤科）
  • 按最终使用者（医院/诊所、癌症治疗中心、学术/研究机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美光学切片市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲光学切片市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区光学切片市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲光学切片市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲光学切片市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球光学切片市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Mauna Kea Technologies
• Boston Scientific Corporation
• Olympus Corporation
• Medtronic plc
• Hologic, Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Cook Medical
• Cardinal Health, Inc.
• NinePoint Medical, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Optical Biopsy Market is projected to expand from USD 1.46 Billion in 2025 to USD 2.32 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.02%. Optical biopsy defines a non-invasive diagnostic method that leverages light-tissue interaction to capture real-time pathological data, thereby eliminating the requirement for physical tissue extraction. The market's growth is largely driven by the rising incidence of oncological conditions and the critical need for early disease detection, which demands frequent and less invasive diagnostic procedures. According to the American Cancer Society, an estimated 2,001,140 new cancer cases were anticipated in the United States in 2024, a rising disease burden that accelerates the demand for rapid diagnostic modalities capable of delivering immediate results for prompt treatment planning.

Despite the clear clinical benefits regarding diagnostic speed and reduced patient trauma, the market encounters significant obstacles related to high capital requirements. The substantial costs involved in purchasing and maintaining sophisticated optical imaging instrumentation limit accessibility, particularly within developing healthcare infrastructures or smaller medical facilities. This financial constraint compels healthcare providers to conduct rigorous cost-benefit analyses, which ultimately slows the procurement rate of these diagnostic systems and hinders broader market penetration.

Market Driver

Technological advancements in optical imaging modalities are fundamentally transforming the optical biopsy landscape by improving diagnostic precision and facilitating real-time tissue assessment. Innovations such as fluorescence-guided surgery and advanced optical coherence tomography are minimizing the need for repeat procedures by enabling surgeons to visualize cancerous margins during operations. A notable example of this progress is the recent regulatory approval of advanced imaging platforms that combine drug-device technologies for superior detection; according to a Lumicell Inc. press release in April 2024, their newly approved LumiSystem demonstrated an 84% diagnostic accuracy in detecting residual cancer during breast-conserving surgery, addressing critical gaps in traditional histopathology and fostering market growth.

The escalating global prevalence of cancer and chronic diseases acts as a primary catalyst for the widespread adoption of optical biopsy systems. As malignancy rates rise, there is an urgent requirement for rapid, non-invasive diagnostic tools capable of handling growing patient volumes without the delays associated with physical tissue processing. Data from the International Agency for Research on Cancer (IARC) in February 2024 indicates that over 35 million new cancer cases are predicted for 2050, representing a 77% increase from 2022 estimates. This surging disease burden correlates directly with increased procurement of advanced diagnostic aids, as evidenced by Mauna Kea Technologies reporting a 42% sales increase to €10.5 million in 2023, driven largely by demand for its confocal laser endomicroscopy solutions.

Market Challenge

High capital requirements pose a substantial barrier to the expansion of the global optical biopsy market. The procurement of these diagnostic systems entails significant upfront expenditures, which restricts accessibility for healthcare facilities operating with limited budgets. This financial burden extends beyond the initial purchase price to include costs associated with regular maintenance, calibration, and the specialized training of medical personnel. Consequently, smaller community hospitals and clinics often defer the adoption of this technology in favor of traditional and more affordable diagnostic methods, effectively confining the usage of optical biopsy systems to large, well-funded medical centers.

This economic constraint directly impedes market penetration by prolonging the decision-making timeline for potential buyers. Healthcare administrators are compelled to perform rigorous cost-benefit analyses, which often results in delayed procurement or the rejection of purchase requests. This hesitation is intensified by broader financial pressures facing the medical sector; for instance, the American Medical Association noted in 2024 that the Medicare physician payment schedule was reduced by 3.4 percent, creating a tighter fiscal environment. This reduction in reimbursement levels limits the discretionary funds available for acquiring advanced instrumentation, thereby slowing the overall growth rate of the optical biopsy market.

Market Trends

The convergence of optical imaging with robotic-assisted surgical systems is establishing a new paradigm in precision surgery by integrating cellular-level visualization directly into robotic platforms. This synergy addresses the critical challenge of intraoperative margin assessment, allowing surgeons to identify occult disease and preserve healthy tissue without delaying the operation for frozen section analysis. The integration enables real-time decision-making during complex procedures, such as TransOral Robotic Surgery (TORS), where identifying tumor boundaries is notoriously difficult; according to a Mauna Kea Technologies press release in January 2025, a case series utilizing this integrated approach demonstrated that surgeons achieved clean margins post-surgery in 100% of cases.

The commercialization of multimodal hybrid imaging platforms is rapidly advancing, driven by the clinical need to consolidate diagnostic workflows into single-catheter solutions. These platforms merge high-resolution structural imaging, such as Optical Coherence Tomography (OCT), with functional physiology measurements to optimize intervention strategies in cardiology. This integration minimizes catheter exchanges and enhances decision-making efficiency during percutaneous coronary interventions by providing simultaneous morphological and physiological data. As highlighted in an October 2025 press release by SpectraWAVE, Inc., the company secured its fifth FDA clearance in just over two years for its AI-enabled X1-FFR platform, underscoring the accelerating industry shift toward versatile, all-in-one optical diagnostic tools.

Key Market Players

• Mauna Kea Technologies
• Boston Scientific Corporation
• Olympus Corporation
• Medtronic plc
• Hologic, Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Cook Medical
• Cardinal Health, Inc.
• NinePoint Medical, Inc.

Report Scope

In this report, the Global Optical Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Biopsy Market, By Technique

• Optical Coherence Tomography (OCT)
• Laser
• Infrared
• Fluorescence
• Spectroscopy
• Others

Optical Biopsy Market, By Application

• Oncological
• Non-Oncological

Optical Biopsy Market, By End User

• Hospitals & Clinics
• Cancer Care Centers
• Academic & Research Institutes
• Others

Optical Biopsy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Biopsy Market.

Available Customizations:

Global Optical Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technique (Optical Coherence Tomography (OCT), Laser, Infrared, Fluorescence, Spectroscopy, Others)
  • 5.2.2. By Application (Oncological v/s Non-Oncological)
  • 5.2.3. By End User (Hospitals & Clinics, Cancer Care Centers, Academic & Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Optical Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Optical Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technique
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Optical Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technique
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Optical Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technique
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Optical Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Optical Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Optical Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Optical Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technique
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Optical Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technique
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Optical Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Optical Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Optical Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Optical Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Optical Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technique
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Optical Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technique
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Optical Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Optical Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Optical Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Optical Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Optical Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Optical Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Optical Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Optical Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Mauna Kea Technologies
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boston Scientific Corporation
• 15.3. Olympus Corporation
• 15.4. Medtronic plc
• 15.5. Hologic, Inc.
• 15.6. Danaher Corporation
• 15.7. Becton, Dickinson and Company
• 15.8. Cook Medical
• 15.9. Cardinal Health, Inc.
• 15.10. NinePoint Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer